Celgene — FY2018 Earnings Presentation
54 slides from Celgene's earnings presentation, Jan 31, 2019
Slide 1: Q4 and Full Year 2018 Conference Call
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD: PURSUITS IN SCIENCE Q4 and Full Year 2018 Conference Call eS January 31, 2019
Slide 2: Speakers and Q&A
Mark Alles, Chairman & Chief Executive Officer David Elkins, Chief Financial Officer Nadim Ahmed, President, Hematology & Oncology Terrie Curran, President, Inflammation & Immunology Jay Backstrom, MD, Chief Medical Officer Q&A
Slide 3: Important Information for Investors and Stockholders
Important ntormation Fr Investors And Stockholders ‘909, as amended, “Se) : oy Seer of rites Sq an Cale tn conan a pospe of Ba tyrs Sautn ana aie on cine of Brot Myers Squbo and Colne NVESTORS AND SECURITY HOLDERS OF BRISTOL MYERS SQUID AND CELGENE ANE URGED TO REAO Hietoni PROXY STATEMENTIOROSPECTU
Slide 4: Cautionary Statement Regarding Forward-Looking Statements
srt es cir my ene yon Aegan Capos ces cn gene ston Sages Ssh nnd Care pong cpt raccoon cash owt she Sen Shae Cage Batten Sasso ones omen apm, even rast afes ans Sard Sgro Mewes, ‘SearsnSetna.ar mayen tan samp eu taan soe opi prea ns pps ones het as jes Cgera Cage ses yy ‘Stone eves tonad ang vars sa
Slide 5: Mark Alles, Chairman & CEO
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD: PURSUITS IN SCIENCE Mark Alles Chairman & Chief Executive Officer
Slide 6: Reaffirming 2020 outlook; accelerating inline and pipeline assets
— Reaffirming 2020 outlook: total revenue of $19-$20B & adj. diluted EPS of >$12.50 Accelerating Inline and Pipeline Assets ~ Five late-stage assets on-track for U.S. launches expected through 2020 — ozanimod, fedratinib, luspatercept, liso-cel and bb2121 - Increasingly productive early R&D engine,
Slide 7: Bristol-Myers Squibb: The Right Transaction for Celgene
Bristol-Myers Squibb: The Right Transaction for Celgene lwo companies with one mission — discover, develop and deliver the most innovative medicines to patients with unmet medical needs across the continuum of care = Recognizes and unlocks significant value for Celgene shareholders — Delivers immedi
Slide 8: David Elkins, Chief Financial Officer
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD: PURSUITS IN SCIENCE David Elkins Chief Financial Officer
Slide 9: Q4:18 & FY:18 Financial Highlights
Q4:18 & FY:18 Financial Highlights vuUy 2018 Operating Results ~ 04:18 Y/Y net product sales grew 16% to $4.0B and adjusted diluted EPS grew 20% to $2.39 ~ 2018 Y/Y net product sales grew 18% to $15.38 and adjusted diluted EPS grew 19% to $8.87 Strong Execution on Operating Metrics = Strong product
Slide 10: Total Net Product Sales Q4:18
$ Millions > Total Net Product Sales $3,479 $2,977 MT% 17% 04:16 4:17 $4,036 116% Contribution to Q4:18 Total Net Product Sales Growth 115.2% 11.3% 10.5% 116.0% Q4:17 Volume Price Fx/ 4:18 Hedge
Slide 11: Total Net Product Sales FY2018
$ Millions > Total Net Product Sales $12,973 $11,185 122% 116% 2016 2017 $15,265 118% 2018 Contribution to 2018 Total Net Product Sales Growth 115.2% 12.9% 2017 Volume Price 0.4% 117.7% Fx/ Hedge 2018
Slide 12: Adjusted Diluted EPS Q4:18
Dollars Per Share > Adjusted Diluted EPS $2.39 $2.00 $1.61 136% 124% 120% Dollars Per Share Contribution to Q4:18 Adjusted Diluted EPS $2.00 $0.30 ($0.12) ($0.04) $0.25 $2.39 Q4:17 Oper. OIE Tax Share Q4:18 Income Rate Count
Slide 13: Adjusted Diluted EPS FY2018
Dollars Per Share > Adjusted Diluted EPS 2016 2017 $8.87 2018 Dollars Per Share Contribution to 2018 Adjusted Diluted EPS $7.44 $0.97 ($0.29) ($0.06) $0.81 $8.87 2017 Oper. OIE TaxRate Share 2018 Income Count
Slide 14: Margins and Expenses
Product Gross Margin R&D Expenses ‘% of revenue SG&A Expenses % of revenue Operating Margin Effective Tax Rate ¢ 4:18 96.0% $919M 22.8% $762M 18.9% 54.4% 15.4% Q | ~80 bps + ~80 bps | ~80 bps | ~70 bps 4-140 bps FY2018 96.4% $3,509M 23.0% $2,747M 18.0% 55.5% 16.5% Avs. FY2017 | ~30 bps 1 ~190 bps 7
Slide 15: Cash and Marketable Securities
($ in Billions) 12/31/18 12/31/17 Cash, Cash Equivalents, Marketable Debt Securities and Publicly-Traded $6.04 $12.04 Equity Securities Cash flow from operations was approximately $5.2B during 20181 In 2018, invested ~$9.7B in new acquisitions? In 2018, purchased ~$6.1B of shares Cegne ‘cated arnt S
Slide 16: 2019 Guidance
Total Revenue REVLIMID® Net Product Sales POMALYST®/IMNOVID® Net Product Sales OTEZLA® Net Product Sales ABRAXANE® Net Product Sales Adjusted Operating Margin Adjusted Tax Rate Adjusted Diluted EPS. Weighted Average Diluted Shares 2019 Guidance $17.0B-$17.2B ~$10.8B ~$2.4B ~$1.9B ~$1.1B ~57.5% ~17.0
Slide 17: Nadim Ahmed, President, Hematology & Oncology
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD: PURSUITS IN SCIENCE Nadim Ahmed (pa President, Hematology & Oncology
Slide 18: Q4:18 & FY:18 Hematology & Oncology Franchise Results
Q4:18 & FY:18 Hematology & Oncology Franchise Results Strong Net Product Sales and Operating Momentum ~ Net product sales: Q4:18 - $3.68, +15% YIY; FY:18 - $13.78 +17% YY Growth Drivers Delivering > REV NscT ~ POMALY > REVU S.and EU = ABRAXANE IO combination U.S. approvals in 1L mTNBC and 1L metasta
Slide 19: REVLIMID and POMALYST Net Sales
REVLIMID® Net Sales ($M) Current Results & Potential Future Growth Drivers $2,188 oa REVLIMID® - Q4:18 net sales ~$2.5B, +16% Y/Y; susct Ee FY:18 net sales ~$9.7B, +18% YIY $60: POMALYST® - Q4:18 net sales $567M, +28% YIY; a FY:18 net sales ~$2.0B, +26% YIY essen S79 O72? Strong growth with contribu
Slide 20: ABRAXANE Current Results & Potential Future Growth Drivers
Current Results & Potent + Q4:18 net sales $269M, +7% Y/Y; + FY:18 net sales ~$1.1B, +7% Y/Y » Potential future growth drivers: Ph Ill apact® trial of ABRAXANE® in adjuvant pancreatic cancer data (event-driven) First approved IO combination regimen for 1L metastatic squamous NSCLC: Pembrolizumab + A
Slide 21: CHANGING THE COURSE OF
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD: PURSUITS IN SCIENCE
Slide 22: Q4:18 & FY:18 I&I Franchise Results
Q4:18 & FY:18 1&l Franchise Results Continued Positive Momentum for OTEZLA® — Achieved updated 2018 revenue guidance = Strong demand driving significant growth across geographies — Favorable access positions in the U.S., key EU markets, and Japan Advancing the OTEZLA® Lifecycle Development Plan — Su
Slide 23: OTEZLA Current Results & Potential Future Growth Drivers
Current Results & Potential Future Growth Drivers 4:18 net sales $448M, +21% YY FY:18 net sales ~$1.68, +26% YIY Continued robust volume-based growth Mainaning U.S. new.o-rand leadership despte increasingly competitive ma leved dynamic market leadership in France; continue {ode fastest postin uptae
Slide 24: Jay Backstrom, MD, Chief Medical Officer
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD: PURSUITS IN SCIENCE Jay Backstrom, MD Chief Medical Officer
Slide 25: Ozanimod Regulatory Filings Supported by Phase III Data
‘Adjusted ARR (95% Cl) ‘ Adjusted ARR (295% Cl) Ozanimod Regulatory Filings Supported by Clinical Efficacy & Safety Data from Two Phase III Trials in Patients with RMS SUNBEAM™ — Over 1 year 31% requetion Poop “SLSgyBton ‘P0.0001 SUNBEAM™ and RADIANCE™ PART B Pooled ‘Summary of Adverse Events ‘P0.00
Slide 26: Ozanimod: Next-Generation S1P Modulator
te Ozanimod: Re Advancing a Next-Generation S1P Modulator for RMS and IBD Ozanimod + Potentially differentiated risk-benefit profile in RMS + U.S. NDA and EU MAA submissions for RMS/RRMS on track for Q1:19 - Non-clinical bridging studies, PK/PD and DDI trials completed + Phill TRUE NORTH™ ulcerative
Slide 27: Fedratinib
Fedratinib Highly selective JAK2 inhibitor Studied in itinil ive and r itinib- sed patients with myelofibrosis NDA submitted for myelofibrosis; U.S. approval expected by year-end 2019 EU MAA submission planned in H1:19 FREEDOM/FREEDOM-2 myelofibrosis trials advancing Ph I/ll ination trial with It Pp
Slide 28: Luspatercept
ispatercep! A Potential Platform Molecule for Chroni + First-in-class erythroid maturation agent *US. and EU U regula) submissions for RS+ MDS and It bet on-track for H1:19 + Broad development strategy = Phill COMMANDS trial in ESA-naive MDS — Randomized Ph Il BEYOND trial in non-transfusion depende
Slide 29: Harnessing Immunotherapy in NHL and CLL
Harnessing Immunotherapy in NHL and CLL Potential best-in-class CD19 CAR T profile + BLA submission expected in H2:19; U.S. approval expected in mid-2020 Early Ph I/II data in R/R CLL (BTK failures) compelling; Pivotal Ph II trial initiating Clinical trials in earlier lines of DLBCL underway - Phill
Slide 30: bb2121 in Multiple Myeloma
jal to Redefine the Treatment of Multiple Myeloma * Potential first-in-class BCMA CAR T for multiple myeloma + Pivotal KarMMa™ trial enrollment completed + U.S. approval in highly refractory MM expected in H2:20 inical program in earlier lines of MM advancing - Phill KarMMa™ 3 in 3° line+ - Phil Kar
Slide 31: Q4 and Full Year 2018 Conference Call
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD: PURSUITS IN SCIENCE Q4 and Full Year 2018 Conference Call eS January 31, 2019
Slide 32: CHANGING THE COURSE OF
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD: PURSUITS IN SCIENCE
Slide 33: Use of Non-GAAP Financial Measures and Reconciliation Tables
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD: PURSUITS IN SCIENCE Use of Non-GAAP Financial Measures and : (pa Reconciliation Tables
Slide 34: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures Use of Non-GAAP Financial Measures GAAP, based on management's view of performance including: + Adjusted research and development expense + Adjusted selling, ‘administrative expense + Adjusted operating margi + Adjusted net income + Adjusted earnings per share pl W
Slide 35: Share-Based Compensation
Share-Based C such as our stock ‘expense, which is non-cash fl fi share-based grants are issued c ; as ‘consider them to be normal, r 1 nature, i lack and/or timing, Upfront Sf a multiyear property rights, P and lack ofp i ds which does not pe |, recurring 2 adjusted financial result ig nature, vari
Slide 36: Restructuring Costs and Certain Other Items
Restructuring Costs results. with lo not freq Certain Other Items: ignifi normal, 1g from financial results individual pl either asa result. ‘our normal basis. While not al ignif fi ia igation-el 1, effective for fiscal year 2018, changes in the fair value of our equity securities ‘2016-01 (Financia
Slide 37: ict
no 2 ict ec =) 2 & Te = Qo oO oO rea oe
Slide 38: nN iS < & iS) < Qo oO oO x
nN 2 8 iS < 2 & iS) < Qo oO oO x
Slide 39: nN iS < & iS) < Qo oO oO x
nN 2 8 iS < 2 & iS) < Qo oO oO x
Slide 40: Appendix
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD: PURSUITS IN SCIENCE Appendix
Slide 41: Advancing a High Quality Pipeline with Significant Potential
Advancing a High Quality Pipeline with Significant Potential Revo? Joana ReEvUMO® | 6270 2, rapn.ae2 roma eee Tietz RRMNE = om sation we “st Usoce THALOMID® | DI EART ——e \ a | ge s010 wot a ‘S se-aoo0 x Be Timnetor 20 tga Bice & =< ‘ Soros Gegggyy seed Ture Soins, TELA’ cc.99677 Poetnntr WG anther
Slide 42: 2019 Financial Performance and Milestones Expected
‘nancial Performance 1 Total revenue $17.08.847.28 D REVLIMID® net sales ~$10.88 1 POMALYST® net sales ~$248 Oi OTEZLAP net sales ~$1.98 i ABRAXANE® net sales ~$1.18 ‘Adj. operating margin ~57 5% 1 Ad, diuted EPS $10.60 to $10.80 lestones Expected for Key Pivotal Assets (zanimod Sao FD zs nS (G_Sate
Slide 43: RRMM Late-Stage/Pivotal Programs
RRMM. RRMM RRMM POMALYST*INNOVID® e221 e121 DT BBRTaTAM-OOT BeETa aa opraista Keca™ Wo Phase 0 W ‘Target Enrollment 559 140 361 “him A POMALYST=nNOVIO™ eS vam | cnt aasom ca ropesiin (toned one rangngitom 5 | 18-48% 107 CART cols ater Design og {Sx 107 CAR T cole ator receiving receiving ymahodepeti
Slide 44: MDS/AML/MF Late-Stage/Pivotal Programs
MDS/AML/MF Late-Stage/Pivotal Programs Patient Population Low risk/IN’ depend induction Al jaintenance ccase Losshahd (Oral azacitidine) (Oral azacitidine) Trial Name AzaWOs.003 case aMt-cot Phase ft Target Enrollment 216 472 on oe Peace Bev eyce west uppotvecare ee) am Am Primary Endpoint | P8C¥ars
Slide 45: MDS/AML/MF Late-Stage/Pivotal Programs: Luspatercept
MDS/AML/MF tient Population ‘Anemia in to Very Intermediate Late-Stage/Pivotal Programs Red Blood Cell Transfusion Dependent Beta-Thalassemi Molecule Lspatercept Luspatercept Trial Name MEDALIST™ BELIEVE™ Phase W Target Enrollment Ey 335 frm spate string dose of 107 0K9 | um: Lspatercent( mae) + bes
Slide 46: ESA Naive MDS Programs
ESA Nalve Very Low, Low or Intermediate Ay Luspatercept IDHIFA® ‘ComMANDS™ TDHENTIFY™ m m 350 6 atorcopt ‘Acm A: IDHIFA 2 7 Aim AL ( ‘supportive care Arm 8: ‘Overall Survival Status ‘rial enrling ‘Tal enrling
Slide 47: Relapsed or Refractory Lymphoma Programs
Relapsed or Refractory NewyDisgrosedFlicular | Unrated AtvaedB-Cal Follicular Lymphoma yep oLecL evuio® Revuio® evunio® TGHENT™ ROBUST Trial Name a ELEVANGE™ a Phase if rf 1 Target Enrollment oe vo31 70 : sum REVLIMIO® (srt dose ArmA: REVLNMO® (10209, 0121 LIMIO®( fnab Semon went et “ie sreeebsrean
Slide 48: Lymphoma Late-Stage/Pivotal Programs
ue Lymphoma Late-Stage/Pivotal Programs A Patient Population Relapsed or Refractory Indolent Lymphoma Relapsed or Refractory Molecule REVLIMIO® vee _ (isccabtagene maraleucet; JCAROI7) MAGNIFY™ a Trial Name pire TRANSCEND-NHL.00% Phase Ww T 500 24 vim KREVLIMID® (10-2079, D1-21) + riuximab (375 mal
Slide 49: Aggressive Lymphoma and CLL Programs
Patient Population ‘Aggressive Relapsed or Refractory B-Cell Lymphoma Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma ap iso-ce so-el (isccabtagene maraleuce,JCARO'7) {isocabtagene marleuce; JCAROT7) iSCEND-CLLO004 Trial Name TRANSCEND WORLD pane Phase 0 vi Target E
Slide 50: Lymphoma Late-Stage/Pivotal Programs
ymphoma Late-Stage/Pivotal Programs {elapsed or Refractory B. Hodgkin Lymphoma: Relapsed or Refractory Ang Cell Lympho TRAN (JCARO17-BOM< 028) Phase i ww Target Enrollment 182 86 Experimental (Oral szactsine 200 mg oF 300 mg QD x 14 days of 28-day ‘oycle ‘Am &: standard of care ($0) per investigator
Slide 51: Late-Stage/Pivotal Programs
Late-Stage/Pivotal Programs Adjuvant Therapy in Surgically Nowy Diagnosed Glioblastoma gnosed Stage Il non cd Pancreati oa tl wnat Col Lung Con Molecule -ABRAXANE® Marizomib Tislekzumab (BGB-A317) PANC-008 BGB-ABIT-NSCLOOT ‘Trial Name pn EORTC-BTG-1709 ppaelieen Phase u i i Target Enrollment 286 750
Slide 52: OTEZLA Scalp Psoriasis and Plaque Psoriasis Programs
Scalp Psoriasis OTEZLAP Mild to Moderate Plaque Psor OTEZLA® Boranz 350.001 PSORaZ2 RELIEF? sTme™ AOvANCE™ 0 0 0 208 x00 4 Tima Phcabo Sr OreaLAe give camrerse” | AA Placbo or 18 vols) (lowed | yn. OTEZLM Design weeks) weeks) Ame ores singin dtr | nm, pero ors2 wees) ‘Am 8 Placebo BI for 16 weeks ob
Slide 53: I&I Late Stage Programs
1&1 Late Stage Programs Moderate to Severe Ulcerative Colitis Moderately to Severely Active Crohn's Disease Moderately to Severely Active Crohn's Disease Patient Population Ozanimod ‘Ozanimod (Ozanimod Trial Name TRUE NORTH™ RPCO1-3201 RPCO1-3202 Phase tr Ww 900 600 Ama: Design 2 ‘em 8: Paco duction
Slide 54: Important Information
Important Information For Investors And Stockholders This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. It does not constitute a prospectus or prospectus equivalent document. No offering of securiti